400-920-2911
上海市杨浦区翔殷路128号1号楼101
Endothelin Receptor
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| CSN13675 | Zibotentan | 186497-07-4 | Zibotentan is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM). |
| CSN12014 | Sulfisoxazole | 127-69-5 | Sulfisoxazole is an antagonist of endothelin receptor that can be used as a sulfonamide antibacterial agent. |
| CSN11008 | Sodium Ferulate | 24276-84-4 | Sodium ferulate is the sodium salt of ferulic acid which is used for the treatment of cardiovascular disease. |
| CSN12974 | Sitaxsentan Sodium | 210421-74-2 | Sitaxsentan sodium has selectory antagonism of endothelin A (ETA) receptor with the IC50 and Ki value of 1.4 nM and 0.43 nM respectively. |
| CSN12975 | Sitaxsentan | 184036-34-8 | Sitaxsentan is a selective endothelin A (ETA) receptor antagonist. |
| CSN17902 | Ro 46-2005 | 150725-87-4 | Ro 46-2005 is an antagonist of endothelin receptor. |
| CSN25744 | IRL-2500 | 169545-27-1 | IRL-2500 is a potent endothelin receptor antagonist with IC50 values of 1.3 and 94 nM for ETB and ETA receptors respectively. |
| CSN23533 | Darusentan | 171714-84-4 | Darusentan is an antagonist of endothelin ETA receptor and it can be used to treat congestive heart failure and hypertension. |
| CSN19760 | Clazosentan | 180384-56-9 | Clazosentan is a potent endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury. |
| CSN18010 | BQ-788 | 173326-37-9 | BQ-788 is a potent and selective endothelin receptor subtype B (ETB) antagonist with IC50 of 1.2 nM (inhibits 125I-labeled endothelin 1 (ET-1) binding to ETB receptors on human Girardi heart cells). |
| CSN17753 | BQ-123 | 136553-81-6 | BQ-123 is a specific antagonist of endothelin A receptor (ETA) and the IC50 is 7.3 nM. |
| CSN12872 | Avosentan | 290815-26-8 | Avosentan is a potent, selective endothelin receptor (ETA receptor) antagonist. |
| CSN13753 | Atrasentan HCl | 195733-43-8 | Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer. |
| CSN10496 | Ambrisentan | 177036-94-1 | Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the endothelin type A receptor (IC50s = 0.251, 0.316, 0.398, 251, and 630 nM for rat preparations of heart, bladder, kidney, lung, and cerebral cortex, respectively). |